Pinheiro Alexandre, Serracarbassa Pedro Durães, Maia Otacílio Oliveira, Takahashi Walter Yukihiko
Setor de Retina e Vítreo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Arq Bras Oftalmol. 2007 Sep-Oct;70(5):784-9. doi: 10.1590/s0004-27492007000500011.
To assess the effect of intravitreal injections of triamcinolone on macular thickness (Stratus-OCT), intra-ocular pressure and visual acuity, in the treatment of diabetic macular edema non-responsive to previous laser photocoagulation, over a 6-month period.
The study included 21 subjects (22 eyes) who underwent complete ophthalmologic examination, measurements of visual acuity and intraocular pressure, and OCT, previously treated with at least 2 laser applications. The study participants were treated with 4 mg/0.1 ml intravitreal triamcinolone. Follow-up visits were scheduled for the 1st day after treatment, and after 1, 3 and 6 months. Visual and anatomical results, as well as possible complications associated with the intravitreal injection procedure were studied.
The study showed a significant reduction in mean macular thickness, assessed by OCT at 1, 3 and 6 months post-treatment (p=0.001), combined with an improvement of the mean visual acuity (p<0.001). Central macular thickness mean+/-SD value on the first visit was 399 (+/-121 microm); it was reduced by 39.9% (239+/-53 microm) at the first month (p<0.001), 35.5% (255+/-93 microm) at the third month (p<0.001), and 18.1% (326+/-135 microm) at the sixth month (p=0.001). The improvement in mean visual acuity was of 18 and 16 letters on the ETDRS table, on the 3rd and 6th month, respectively. Reported complications were an increase in intraocular pressure in seven eyes (33.3% of the cases).
A reduction in mean retinal thickness was observed throughout the entire follow-up period, with significant increase in macular thickness between the 3rd and 6th month. The mean visual acuity showed statistically significant improvement at the end of the follow-up period, but no change was noticed between the 3rd and 6th month.
评估玻璃体内注射曲安奈德对黄斑厚度（Stratus-OCT）、眼压和视力的影响，用于治疗对先前激光光凝无反应的糖尿病性黄斑水肿，为期6个月。
该研究纳入21名受试者（22只眼），这些受试者接受了全面的眼科检查、视力和眼压测量以及OCT检查，此前至少接受过2次激光治疗。研究参与者接受了4mg/0.1ml玻璃体内曲安奈德治疗。在治疗后第1天以及1、3和6个月安排了随访。研究了视觉和解剖学结果以及与玻璃体内注射 procedure相关的可能并发症。
研究显示，治疗后1、3和6个月通过OCT评估的平均黄斑厚度显著降低（p = 0.001），同时平均视力有所改善（p < 0.001）。首次就诊时中央黄斑厚度的平均±标准差为399（±121微米）；在第1个月时降低了39.9%（239±53微米）（p < 0.001），在第3个月时降低了35.5%（255±93微米）（p < 0.001），在第6个月时降低了18.1%（326±135微米）（p = 0.001）。在第3个月和第6个月时，ETDRS视力表上平均视力分别提高了18和16个字母。报告的并发症是7只眼（占病例的33.3%）眼压升高。
在整个随访期间观察到平均视网膜厚度降低，在第3个月至第6个月黄斑厚度显著增加。随访期结束时平均视力有统计学显著改善，但在第3个月至第6个月之间未观察到变化。
